EternoGen has received an accumulated investment of about $9M which has driven product development and optimization, and is presently raising a series B round.
Present investors include angel investors, management team members, a technology incubator, and a major European pharmaceutical company.
Current investors include:
Commercialisation in Europe and Asia
EternoGen is currently seeking commercialising of RPC Pure Collagen in Europe. EternoGen’s success factors are:
- Large and rapidly growing market
- Clear customer and consumer need
- Superior and unique technology
- Experienced team
- Attractive acquisition target
For more information
Please contact us.